The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

(2015) Avi Ashkenazi   JOURNAL OF CLINICAL INVESTIGATION

AXL Mediates TRAIL Resistance in Esophageal Adenocarcinoma

(2015) Jun Hong et al.   NEOPLASIA

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Axl receptor tyrosine kinase expression in breast cancer

(2014) Timothy M D'Alfonso et al.   JOURNAL OF CLINICAL PATHOLOGY

E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis

(2014) Min Lu et al.   MOLECULAR CELL

Death receptor agonist therapies for cancer, which is the right TRAIL?

(2013) Pamela M. Holland   CYTOKINE & GROWTH FACTOR REVIEWS

P-cadherin and vimentin are useful basal markers in breast cancers

(2013) Julia Y.S. Tsang et al.   HUMAN PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis

(2011) S. V. Garimella et al.   MOLECULAR CANCER RESEARCH

Molecular Stratification of Triple-Negative Breast Cancers

(2011) C. M. Perou   ONCOLOGIST

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

(2008) Monzur Rahman et al.   BREAST CANCER RESEARCH AND TREATMENT

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION